The topic of this rewrite is HIV-related toxoplasmosis, a rare but serious co-infection that can involve both the brain and the heart. The core message remains: immunocompromised individuals, especially those with advanced HIV, face heightened risks from Toxoplasma gondii, and timely, accurate diagnosis is crucial to prevent fatal outcomes.
A concise overview helps beginners grasp the key ideas: toxoplasmosis is caused by T. gondii, a widespread protozoan parasite. About one-third of the global population carries the infection, though the impact varies by region and lifestyle. In people with healthy immune systems, it often remains silent or causes mild flu-like symptoms. In contrast, immunocompromised patients—such as those with HIV and low CD4 counts—are at risk for reactivation and severe disease, commonly presenting as cerebral toxoplasmosis, which can cause headaches, seizures, neurological deficits, and altered consciousness. Cardiac involvement is rarer but serious and is frequently missed, sometimes only identified after death.
This particular case illustrates several lessons. First, clinicians should maintain a high index of suspicion for toxoplasmosis in newly diagnosed HIV patients with very low CD4 counts who present with neurological or systemic symptoms, even when malaria is a plausible alternative diagnosis in resource-limited settings. Misdiagnosis or delayed diagnosis can occur if testing focuses on the most common regional diseases or if there is over-reliance on rapid tests that may yield false results. Second, coordinating care at higher-level facilities with imaging (CT or MRI), infectious-disease expertise, and multidisciplinary teams improves diagnostic accuracy and treatment planning.
In the reported case, the patient was treated for malaria based on a positive rapid diagnostic test, and early cerebral toxoplasmosis was not suspected. Although malaria treatment led to transient improvement, the underlying toxoplasmosis progressed, and the patient ultimately died from multifocal CNS and cardiac involvement. Autopsy confirmed concurrent cerebral and cardiac toxoplasmosis, underscoring how the disease can manifest in multiple organ systems and how a single, initial presentation can mask a more disseminated infection.
Diagnosis of T. gondii infection relies on a combination of clinical assessment, serology (to detect anti-toxoplasma IgG/IgM), molecular methods like PCR (targeting the B1 gene or 529 bp repeat), and histopathology showing bradyzoites and tachyzoites in tissue. Imaging—CT, MRI, ultrasound, or nuclear imaging—supports diagnosis but is not definitive on its own. In HIV patients, histopathological confirmation remains the gold standard when feasible.
Treatment for cerebral and systemic toxoplasmosis typically uses a combination of pyrimethamine, sulfadiazine, and leucovorin (folinic acid) to reduce hematologic toxicity, usually for at least 4–6 weeks or longer until both clinical and radiological improvement are observed. Alternatives exist for sulfadiazine intolerance, such as pyrimethamine with clindamycin or atovaquone. In cases with cerebral edema, corticosteroids may be used cautiously, balancing benefits against potential risks in latent infections. For HIV-positive individuals, restoring immune function through antiretroviral therapy (ART) is essential. After the acute phase, secondary prophylaxis with the same triple-drug regimen is recommended until the CD4 count stabilizes above approximately 200 cells/µL.
This case also highlights several practical lessons. Early referral to a well-equipped facility with diagnostic imaging and infectious-disease support could profoundly influence outcomes. Relying solely on malaria testing without confirming with blood smears or parasite confirmation can lead to misdiagnosis. Patient adherence to treatment and follow-up is critical, as noncompliance can drastically worsen prognosis, especially in advanced HIV with opportunistic infections.
From a broader perspective, cerebral toxoplasmosis is the most common manifestation in this population, but cardiac involvement, though rare, deserves attention because it can cause arrhythmias, heart failure, and sudden deterioration. When dealing with immunocompromised patients who deteriorate rapidly, clinicians should consider disseminated toxoplasmosis and perform a thorough evaluation across organ systems, even if initial presentations point elsewhere.
If the audience has one takeaway, it is this: in people living with HIV, toxoplasmosis must remain high on the differential diagnosis list when neurological symptoms or acute systemic changes appear, especially when CD4 counts are severely depressed. Asking probing questions such as, “Could there be more than one opportunistic infection at play here?” helps prevent tunnel vision.
Would a broader initial diagnostic protocol—integrating rapid malaria testing with early neuroimaging and toxoplasmosis-directed testing—improve outcomes in resource-limited settings, or would it strain already overburdened healthcare systems? Share thoughts in the comments.
